|
Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients. Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients. conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients. Clinical research trials and Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients. healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients.. Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients. Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients. clinical trial. Subjects frequently obtain the most expert healthcare possible for their Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients. condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "O" Clinical Trials Conditions > Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients.  Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients.
Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients.
For Condition: Sezary Syndrome,Mycosis Fungoides,Lymphoma, T-Cell, Cutaneous
Status: Recruiting
Sponsor(s): Ligand Pharmaceuticals ,
Synopsis: The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in CTCL patients whose tumors do not express CD25.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: - Patient must have been previously enrolled in Protocol 93-04-11 and randomized to the placebo arm; or the patient met all eligibility criteria for protocol 93-04-11 other than the expression of CD25 on CTCL tumor cells. - CTCL disease Stage Ia-III. - History of less than or equal to 3 previous therapies. Repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. Only 1 prior combination cytotoxic chemotherapy regimen is permitted. Topical or systemic steroids are not considered a therapy. - Patient must have evaluable or measureable disease. Lymph node involvement no greater than LN2. No CTCL involvement of bone marrow. - No significant pulmonary or cardiac disease. No active CNS, kidney, or liver disease. - No systemic infections. - ECOG performance status of 0 or 1.
Total Enrollment: 86
Location and Contact Information:
Overall Study Official:
GordonBray, Study Director, Ligand Pharmaceuticals
Haematology Research Center RAMS *Recruiting*
Moscow, ,
Russian Federation
Recruiting
Blokhin Russian Cancer Research Center, RAMS *Recruiting*
Moscow, ,
Russian Federation
Recruiting
Krankenhaus der Stadt Wien *Recruiting*
Vienna, ,
Austria
Recruiting
Central Research Institute of Skin and Venereal Diseases *Recruiting*
Moscow, ,
Russian Federation
Recruiting
Medical Academy in Warsaw, Central Hospital *Recruiting*
Warsaw, ,
Poland
Recruiting
Medical Academy in Gdansk, Dept. of Hematology *Recruiting*
Gdansk, ,
Poland
Recruiting
Peter MacCallum Cancer Institute *Recruiting*
Melbourne, ,
Australia
Recruiting
Regional Oncological Center, Dept. of Chemotherapy *Recruiting*
Lodz, ,
Poland
Recruiting
LKH Universitatsklinikum Graz *Not yet recruiting*
Graz, ,
Austria
Not yet recruiting
Universitatskrankenhaus Eppendorf *No longer recruiting*
Hamburg, ,
Germany
No longer recruiting
Universitatsklinikum Charite *Recruiting*
Berlin, ,
Germany
Recruiting
University of Texas, M.D. Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting
City Hospital *Recruiting*
Nottingham, ,
United Kingdom
Recruiting
St. John's Institute of Dermatology *Recruiting*
London, ,
United Kingdom
Recruiting
Oncological Center *Recruiting*
Warsaw, ,
Poland
Recruiting
J.W. Goethe University Frankfurt *Recruiting*
Frankfurt, ,
Germany
Recruiting
University Clinic, GHS *Recruiting*
ESSEN, ,
Germany
Recruiting
The Medical University of Warsaw, Central Clinical Hospital *Recruiting*
Warsaw, ,
Poland
Recruiting
Burdenko Main Military Clinical Hospital *Recruiting*
Moscow, ,
Russian Federation
Recruiting
Universitatsspital Zurich Dermatologische Klinik *Not yet recruiting*
Zurich, ,
Switzerland
Not yet recruiting
Klinika Hematologii *Recruiting*
Lublin, ,
Poland
Recruiting
Southampton General Hospital *Recruiting*
Southampton, ,
United Kingdom
Recruiting
University of Erlangen *Recruiting*
Erlangen, ,
Germany
Recruiting
St. Petersburg Pavlov State Medical University *Recruiting*
St Petersburg, ,
Russian Federation
Recruiting
Jewish General Hospital *Recruiting*
Montreal, Quebec,
Canada
Recruiting
Hamilton Regional Cancer Center *Recruiting*
Hamilton, Ontario,
Canada
Recruiting
Cross Cancer Centre *Recruiting*
Edmonton, Alberta,
Canada
Recruiting
Universitatsklinikum Munster *Recruiting*
Munster, ,
Germany
Recruiting
Additional Information:
Study ID Numbers: 93-04-14;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00051012
Other Sezary Syndrome Studies:
1. Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) with Yttrium-90 Radiolabeled Anti-Tac
2. Phase I/II Multi-Center, Open Label Study of CpG 7909 in Patients with Cutaneous T-Cell Lymphoma
3. Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients.
4. A Safety/Efficacy Study of SGN-30 (Antibody) in Patients with Refractory or Recurrent CD30+ Hematologic Malignancies
5. Randomized double-blind study of ONTAK (denileukin diftitox) in cutaneous T-cell lymphoma (CTCL) patients.
Related Studies:
Other Sezary Syndrome Clinical Trials
Other Clinical Trials
Other Warsaw Clinical Trials
Open label study of ONTAK (denileukin diftitox) in previously treated Cutaneous T-cell Lymphoma patients.
|
|
|
|
|
|
|
|
